Announcements

16 Nov, 2026

(Q1 Un-audited): EPS was Tk. 0.30 for July-September 2026 as against Tk. 0.50 for July-September 2025; NOCFPS was Tk. (6.72) for July-September 2026 as against Tk. (9.28) for July-September 2025. NAV per share was Tk. 13.83 as on September 30, 2026 and Tk. 13.53 as on June 30, 2026.

16 Nov, 2026

(Q1 Un-audited): Consolidated EPS was Tk. (0.48) for July-September 2026 as against Tk. (0.55) for July-September 2025; Consolidated NOCFPS was Tk. 0.33 for July-September 2026 as against Tk. 0.65 for July-September 2025. Consolidated NAV per share was Tk. 44.83 as on September 30, 2026 and Tk. 45.31 as on September 30, 2025.

16 Nov, 2026

(Cont. News of ORIONINFU): The decline in sales was caused by continuing constraints on importing raw materials, which affected operations and business activities. NOCFPS increased to BDT 1.44 from BDT 0.50 compared to the previous corresponding period through effective cash management in payment to suppliers and for operating expenses. (end)

16 Nov, 2026

(Q1 Un-audited): EPS was Tk. (0.07) for July-September 2026 as against Tk. 0.57 for July-September 2025; NOCFPS was Tk. 1.44 for July-September 2026 as against Tk. 0.50 for July-September 2025. NAV per share was Tk. 16.20 as on September 30, 2026 and Tk. 16.27 as on June 30, 2026. Reasons for deviation: EPS decreased to BDT (0.07) from BDT 0.57 compared to the previous corresponding period, primarily due to a significant decrease in sales revenue. (cont.)

16 Nov, 2026

There will be no price limit on the trading of the shares of the Company today (16.11.2026) following its corporate declaration.

16 Nov, 2026

The Board of Directors has recommended No Dividend for the year ended June 30, 2026. Date of AGM: 30.12.2026, Time: 11:00 AM. Venue: Virtual Digital Platform. Record Date: 26.11.2026. The Company has also reported EPS of Tk. 0.09, NAV per share of Tk. 16.57 and NOCFPS of Tk. 0.73 for the year ended June 30, 2026 as against Tk. 0.32, Tk. 17.54 and Tk. (0.84) respectively for the year ended June 30, 2025.

16 Nov, 2026

(Cont. News of ORIONPHARM): Reason for deviation: Consolidated NOCFPS increased to BDT 1.20 from BDT 0.65 compared to the previous period through effective cash management in payment to suppliers and for operating expenses. (end)

16 Nov, 2026

(Q1 Un-audited): Consolidated EPS was Tk. (0.26) for July-September 2026 as against Tk. (0.30) for July-September 2025; Consolidated NOCFPS was Tk. 1.20 for July-September 2026 as against Tk. 0.65 for July-September 2025. Consolidated NAV per share (Including revaluation surplus) was Tk. 82.96 as on September 30, 2026 and Tk. 84.15 as on June 30, 2026. Consolidated NAV per share (Excluding revaluation surplus) was Tk. 75.19 as on September 30, 2026 and Tk. 76.41 as on June 30, 2026. (cont.)

16 Nov, 2026

(Q1 Un-audited): EPS was Tk. (0.06) for July-September 2026 as against Tk. (0.10) for July-September 2025; NOCFPS was Tk. (0.01) for July-September 2026 as against Tk. 0.02 for July-September 2025. NAV per share was Tk. 15.71 as on September 30, 2026 and Tk. 15.77 as on September 30, 2025.

16 Nov, 2026

(Q1 Un-audited): EPS was Tk. 0.02 for July-September 2026 as against Tk. 0.04 for July-September 2025; NOCFPS was Tk. 0.01 for July-September 2026 as against Tk. 0.02 for July-September 2025. NAV per share was Tk. 20.35 as on September 30, 2026 and Tk. 20.39 as on September 30, 2025.